Thrombopoietin receptor agonist
Lusutrombopag
Brand names: Mulpleo
Adult dose
Dose: 3mg PO OD for 7 days, starting 8–14 days before scheduled procedure
Route: PO
Frequency: OD x 7 days
Clinical pearls
- Severe thrombocytopenia in chronic liver disease prior to invasive procedure (target ≥50)
- Time procedure 9–14 days after first dose
Contraindications
- Hypersensitivity
- Active thromboembolism (caution)
Side effects
- Headache
- Nausea
- Thrombosis (esp. in chronic liver disease, including portal vein thrombosis)
Monitoring
- Platelets weekly during course and 2 weeks after
- Doppler if VTE risk
Reference: BNF; NICE TA617; SmPC; https://bnf.nice.org.uk/drugs/lusutrombopag/. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Pathways
- Major Haemorrhage / Massive Transfusion · BCSH; RCOA; RCEM; RCS — BCSH Guidelines
- Anaemia Investigation · BSH / NICE
- Splenomegaly Workup · BSH; BMJ Best Practice
- Deep Vein Thrombosis Diagnosis and Treatment · NICE CG144 / NICE NG158
- Sickle Cell Crisis · BSH 2021 / BCSH
- Neutropenic Sepsis · NICE CG151 2012 / ESMO